Ratings AdaptHealth Corp.

Equities

AHCO

US00653Q1022

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
10.26 ^USD	-0.87%		+3.01%	+40.74%

17/04	AdaptHealth Names Suzanne Foster as CEO	MT
17/04	AdaptHealth Names Suzanne Foster CEO	DJ

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past twelve months, EPS forecast has been revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

Low profitability weakens the company.
The group shows a rather high level of debt in proportion to its EBITDA.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
ADAPTHEALTH CORP.	+40.74%	1.37B	D+
ABBOTT LABORATORIES	-3.79%	184B	C+
MEDTRONIC PLC	-0.84%	108B	C
BECTON, DICKINSON AND COMPANY	-3.75%	67.8B	A
DEXCOM, INC.	+3.45%	51.05B	B-
CENCORA, INC.	+9.04%	44.67B	B-
HOYA CORPORATION	+3.40%	41.78B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.21%	26.78B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.66%	26.59B	A-
TERUMO CORPORATION	+15.23%	25.86B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes